Literature DB >> 6803747

Experimental stroma herpes simplex keratitis. Influence of treatment with topical bromovinyldeoxyuridine and trifluridine.

P C Maudgal, E De Clercq, J Descamps, L Missotten, J Wijnhoven.   

Abstract

Two compounds, bromovinyldeoxyuridine ([E]-5-[2-bromovinyl]-2'-deoxyuridine) and trifluridine (5-trifluoromethyl-2' deoxyuridine) were compared for their efficacy in the topical treatment of experimental stroma herpetic keratitis produced by the injection of live herpes simplex virus, type 1, into the corneal stroma of rabbits. The trifluridine was used as 1% eyedrops, whereas bromovinyldeoxyuridine was used as either 0.1% or 0.5% eyedrops. All three treatment regimens caused a substantial healing of stroma disease in comparison with placebo treatment. The bromovinyldeoxyuridine (whether used as 0.1% or 0.5%) proved superior to 1% trifluridine eyedrops when the treatment was started one day after virus inoculation. However, bromovinyldeoxyuridine and trifluridine were equally effective if the treatment was started seven days after infection. The 0.5% bromovinyldeoxyuridine eyedrops seemed to be more effective in controlling the complicating severe iritis and secondary glaucoma than either 0.1% bromovinyldeoxyuridine or 1% trifluridine. No toxic effects were observed with bromovinyldeoxyuridine in any eye, whereas 1% trifluridine produced punctate epitheliopathy in some eyes.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6803747     DOI: 10.1001/archopht.1982.01030030655027

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  8 in total

1.  The enigma of herpes stromal disease.

Authors:  J McGill
Journal:  Br J Ophthalmol       Date:  1987-02       Impact factor: 4.638

2.  Influence of (E)-5-(2-bromovinyl)-2'-deoxyuridine on corneal epithelium healing.

Authors:  P C Maudgal; N De Kimpe; E De Clercq; J Descamps; L Missotten; A Geysen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1982       Impact factor: 3.117

3.  Bromovinyldeoxyuridine and interferon treatment in ulcerative herpetic keratitis: a double masked study.

Authors:  O P van Bijsterveld; P J Meurs; E de Clercq; P C Maudgal
Journal:  Br J Ophthalmol       Date:  1989-08       Impact factor: 4.638

4.  Treatment of experimental herpes simplex virus encephalitis with (E)-5-(2-bromovinyl)-2'-deoxyuridine in mice.

Authors:  E de Clercq; Z X Zhang; I S Sim
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

5.  Randomised double-blind trial of bromovinyldeoxyuridine (BVDU) and trifluorothymidine (TFT) in dendritic corneal ulceration.

Authors:  W J Power; A Benedict-Smith; M Hillery; K Brady; L M Collum
Journal:  Br J Ophthalmol       Date:  1991-11       Impact factor: 4.638

6.  Corneal epithelial dysplasia after trifluridine use.

Authors:  P C Maudgal; B Van Damme; L Missotten
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1983       Impact factor: 3.117

7.  Topical BVDU plus low-dosage steroids in the treatment of chronic relapsing zoster keratouveitis. A pilot study.

Authors:  C Ameye; R Sundmacher; E de Clercq
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

Review 8.  An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014.

Authors:  Erik De Clercq
Journal:  Acta Pharm Sin B       Date:  2015-11-02       Impact factor: 11.413

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.